ArticleMedical science monitor : international medical journal of experimental and clinical research2026
Development and Validation of a Predictive Model Combining [18F] FDG PET/CT and the Suidan Score for Primary Optimal Cytoreduction in Advanced High-Grade Serous Ovarian Cancer: A Retrospective Cohort Study.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND For patients with advanced ovarian cancer undergoing cytoreductive surgery, achieving optimal surgical outcomes has significant clinical implications for the design of adjuvant therapy and surveillance strategies. This retrospective, single-center cohort study aimed to develop a radiomics model based on preoperative PET-CT imaging parameters to predict optimal cytoreductive surgery outcomes, thereby providing clinical decision-making support to improve the prognosis of patients with advanced ovarian cancer. MATERIAL AND METHODS Patients with clinically staged IIIC-IVB high-grade serous ovarian carcinoma (HGSOC) who underwent primary cytoreductive surgery between October 2020 and October 2023 were enrolled and divided into training and validation cohorts. A radiomics model based on preoperative PET-CT was developed, and its performance was quantitatively evaluated and compared within the validation cohort. Subsequently, the PET-CT radiomics model was combined with the Suidan score to generate a combined model. RESULTS Optimal cytoreduction rates were 72.86% (training) and 75.0% (validation). The PET-CT radiomics model demonstrated superior discriminative ability (AUC: 0.808, 95%CI: 0.665-0.951) compared to the Suidan score (AUC: 0.773, 95%CI: 0.615-0.931) in validation. The combined model achieved the highest predictive performance (AUC: 0.836, 95%CI: 0.706-0.966), with sensitivity 81.8%, specificity 83.9%, PPV 64.3%, NPV 92.9%, and accuracy 83.3%. CONCLUSIONS The combined model integrating PET-CT radiomics and Suidan score provides accurate preoperative prediction of cytoreductive outcomes, optimizing treatment strategies for advanced ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.